Dr. Murray Krahn is the Director of THETA (Toronto Health Economics and Technology Assessment Collaborative); F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto; Professor in the Faculties of Medicine and Pharmacy, University of Toronto; Senior Scientist at the Toronto General Hospital Research Institute; and Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto. He is also an attending physician in the division of General Internal Medicine at the University Health Network, Toronto. He completed a Master's Degree in Clinical Epidemiology at McMaster University, and a Clinical Fellowship in Medical Decision Making at the New England Medical Centre in Boston. Dr. Krahn's research program focuses on the use of decision analytic methods to examine health policy and health decision-making. He leads one of the leading technology assessment institutes in the country.
My central area of research interest has been the application of decision analysis and economic evaluation to broad questions of health and clinical policy. This methodologic focus has been expressed in a variety of content areas including prostate cancer and viral hepatitis. More recent interests include evaluating the role of disease specific utility assessment, using administrative data to build longitudinal cost models, and evaluating the role of health technology assessment in pharmaceutical reimbursement decisions.
J Hum Genet. 2019 Dec 18;:
Mapping the University of Washington Quality of life questionnaire onto EQ-5D and HUI-3 indices in patients with head and neck cancer.
Head Neck. 2019 Nov 24;:
PLoS One. 2019;14(11):e0225366
Picturing ELSI+: a visual representation of ethical, legal, and social issues, and patient experiences in Health Technology Assessment in Canada.
Int J Technol Assess Health Care. 2019 Nov 15;:1-10
Estimation of fibrosis progression rates for chronic hepatitis C: a systematic review and meta-analysis update.
BMJ Open. 2019 Nov 11;9(11):e027491
Sleep Med. 2019 Jul 22;65:45-53
Value Health Reg Issues. 2019 Nov 01;22:7-14
Long-term morbidity and mortality in a Canadian post-transfusion hepatitis C cohort: over 15 years of follow-up.
J Viral Hepat. 2019 Oct 26;:
Patterns of Care and Costs for Older Patients With Colorectal Cancer at the End of Life: Descriptive Study of the United States and Canada.
J Oncol Pract. 2019 Oct 24;:JOP1900061
Cancer Invest. 2019 Nov 04;:1-11
Senior Scientist, Toronto General Hospital Research Institute (TGHRI)
Director of THETA (Toronto Health Economics and Technology Assessment Collaborative)
F. Norman Hughes Chair in Pharmacoeconomics at the Faculty of Pharmacy, University of Toronto
Professor in the Faculties of Medicine and Pharmacy, University of Toronto
Adjunct Scientist at the Institute for Clinical Evaluative Sciences, Toronto.